Workflow
Enzo Biochem(ENZ)
icon
Search documents
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
ZACKS· 2024-12-19 14:51
Core Viewpoint - Enzo Biochem, Inc. has experienced a significant decline in stock price and revenue, attributed to challenging market conditions and reduced orders from key customers [1][9]. Revenue and Earnings Performance - The company reported revenues of $6.2 million for the first quarter of fiscal 2025, a decrease of 20.4% from $7.8 million in the same quarter last year [2]. - The net loss from continuing operations narrowed to $3.1 million, or $0.07 per share, compared to a loss of $5.7 million, or $0.11 per share, in the prior year [2]. Operating Costs and Margins - Total operating costs decreased by 25.9% year over year to $9.8 million, driven by reductions in R&D, SG&A, and legal expenses [3]. - Gross margins declined to 41% from 44% due to inventory disposals related to a portfolio optimization initiative [3]. Key Business Metrics - R&D spending fell by 33.8% year over year to $0.6 million, reflecting a strategic shift towards manufacturing [5]. - SG&A expenses decreased by 30.3% year over year to $4.9 million, attributed to lower severance costs and reduced share-based compensation [5]. - Legal expenses dropped by 57.4% year over year to $0.5 million as the company moved past litigation related to ransomware attacks [5]. Foreign Exchange and Interest Income - The company recorded foreign exchange losses of $0.2 million, an improvement from the $1 million loss in the prior year [6]. - Interest income decreased by 36.5% to $0.6 million from $0.9 million, due to a lower cash balance and declining interest rates [6]. Geographic Revenue Performance - Revenues from the United States fell by 18.8% to $3.8 million, while revenues from Europe plunged by 22.2% to $1.7 million [7]. - Revenues from Asia Pacific decreased by 24% to $0.8 million, attributed to weakened market demand across all customer bases [8]. Management Commentary - Management noted a challenging demand environment in the life sciences tools sector, impacting revenues across all regions [9]. - Cost containment measures have been implemented, and a $5 million release from an escrow account related to a previous asset sale improved liquidity [9]. Guidance and Outlook - While specific guidance was not provided, management expressed confidence in meeting operational requirements for at least the next 12 months based on available working capital of $36.3 million [10]. Other Developments - No significant acquisitions or restructuring activities were reported, but the company settled multiple legal disputes stemming from a ransomware attack [11].
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update
Globenewswire· 2024-12-16 21:17
Core Insights - Enzo Biochem, Inc. reported a revenue decline of 20% year-over-year for the fiscal first quarter, totaling $6.2 million, attributed to decreased market demand in the life sciences tools sector [2][11] - The company ended the quarter with cash and cash equivalents of $47.7 million, a decrease from $52.4 million at the end of the previous fiscal year [2][12] - A special cash dividend of $0.10 per share was declared and paid to shareholders on December 2, 2024 [3] Financial Performance - The gross profit for the first quarter was $2.3 million, representing a gross profit margin of 37%, down from 44% in the same quarter of the previous year [11] - The operating loss for the quarter was $3.6 million, an improvement from a loss of $5.5 million in the prior year [11] - The net loss from continuing operations was $3.1 million, compared to a loss of $5.7 million in the same period last year [11] Balance Sheet Highlights - As of October 31, 2024, total assets were reported at $75.3 million, down from $85.8 million at the end of the previous fiscal year [12] - Stockholders' equity decreased to $47.7 million from $56.1 million [12] - Working capital was reported at $36.3 million, down from $45.2 million [12] Recent Developments - Jon Couchman was appointed as a director and member of several committees, bringing significant public company experience [4] - The company continues to focus on its Life Sciences division, which includes a wide range of products for translational research and drug development [5]
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
ZACKS· 2024-10-30 16:50
Enzo Biochem, Inc. (ENZ) delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period. Enzo Biochem's Revenues in Detail Enzo Biochem's Life Sciences Products reporting unit operates in one reportable segment, Products. The company's Products revenues were $7.5 million in the fiscal fourth quarter, down 16% year over year. This was due to a shift in ordering patterns. The company's Products revenues were $ ...
Enzo Biochem(ENZ) - 2024 Q4 - Annual Results
2024-10-30 00:02
Exhibit 99.1 Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights ● The Company's revenues ...
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
GlobeNewswire News Room· 2024-10-29 23:59
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers ...
Enzo Biochem: Is This Time Finally Different?
Seeking Alpha· 2024-07-17 04:49
ViktorCap If you're a shareholder of Enzo Biochem (NYSE:ENZ), you're likely frustrated. The investment thesis hasn't changed much in two years; however, shareholders, have been bludgeoned by one thing after another while awaiting Enzo's liquidation following their 2023 sale of the Clinical Labs business to Labocrp Holdings (LH). Is it finally time to buy the beaten-down story, or are investors better off avoiding this mess? There are multiple activists involved in the stock, and the new chairman brings a tr ...
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
ZACKS· 2024-06-20 13:46
Enzo Biochem, headquartered in Farmingdale, NY, has carved a niche in molecular diagnostics. It provides an extensive array of technical platforms and reagent sets for biomedical research and translational science. The company's Life Science division supports a diverse range of applications, including cell biology and genomics, among others. The company maintains a robust balance sheet with $57.2 million in cash as of the fiscal third quarter, despite a reduction due to a significant paydown of accounts pay ...
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
ZACKS· 2024-06-14 18:20
Core Insights - Enzo Biochem, Inc. reported a loss per share of 4 cents from continuing operations in Q3 of fiscal 2024, an improvement from a loss of 16 cents per share in the same quarter last year [1] - The company achieved a net loss of $2.1 million from continuing operations, significantly narrower than the $7.9 million loss reported in the prior year [6] - The gross profit increased by 24.1% to $3.7 million, with gross margin expanding by 633 basis points to 46.5% [21] Revenue Analysis - Total revenues for the Asia Pacific segment were $0.9 million, reflecting a 15.4% increase year-over-year [3] - The Europe segment generated revenues of $2.4 million, up 39.8% year-over-year, attributed to increased marketing efforts in drug development product sales [14] - Products revenues reached $8 million in Q3, marking a 7.2% increase year-over-year, driven by strong performance in Europe and Asia Pacific [13][14] Expense Management - Selling, general and administrative expenses decreased by 27.9% to $4.5 million [4] - Research and development expenses fell by 31.6% year-over-year to $0.6 million [4] - Adjusted operating expenses totaled $5.1 million, down 28.4% year-over-year [4] Profitability Metrics - Adjusted EBITDA for the quarter was a loss of $1.2 million, an improvement from the loss of $3.6 million in the previous year [16] - Adjusted operating loss was $1.4 million, narrower than the adjusted operating loss of $4.1 million reported a year ago [22] Liquidity and Debt - Cash and cash equivalents at the end of Q3 were $57.2 million, down from $60.2 million at the end of Q2 [11] - Total debt at the end of Q3 was $2.7 million, slightly down from $2.8 million at the end of Q2 [23] - Cumulative net cash used in operating activities increased to $25.2 million from $19.9 million a year ago [17] Strategic Developments - The company launched an enhanced website with e-commerce functionality aimed at improving customer access to products and support, which is expected to positively impact stock performance [24]
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
GlobeNewswire News Room· 2024-06-13 20:20
Core Viewpoint - Enzo Biochem, Inc. reported significant financial improvements in its Life Science division for the fiscal third quarter ended April 30, 2024, with a focus on drug development tools driving growth and margin expansion [2][23]. Financial Performance - The Life Science division's third-quarter revenue reached $8.0 million, a 7% increase year-over-year, marking four consecutive quarters of revenue growth [2]. - Year-to-date revenue for the nine months ended April 30, 2024, was $24.4 million, reflecting a 10% improvement compared to the same period in the prior year [2]. - The gross margin for the third quarter improved to 47%, up 700 basis points from 40% year-over-year, with a nine-month year-to-date margin also at 47%, representing a 900 basis point improvement [2]. - The Life Science division reported an operating income of $0.3 million for the third quarter, a turnaround from a $1.0 million operating loss in the prior year [2]. - The net loss from continuing operations for Q3 FY24 was $2.1 million, or ($0.04) per common share, compared to a net loss of $7.9 million, or ($0.16) per common share in the prior year [2]. Cash Position and Debt Management - Enzo ended the third quarter with cash and cash equivalents of $57.2 million, a decrease of $3.1 million during the quarter [2]. - The outstanding principal of the Company's debentures of $3.6 million was paid in full on May 20, 2024, upon maturity [3]. Strategic Developments - The Company launched an enhanced website with e-commerce functionality in May 2024, aimed at improving customer access to products and support [3]. - The transition to a focused manufacturer of Life Science tools is progressing favorably, with significant revenue growth and margin expansion reported [23]. Market Position and Future Outlook - Enzo Biochem is recognized as a pioneer in molecular diagnostics, with a comprehensive portfolio supporting biomedical research and translational science needs [4]. - The Company has a broad intellectual property portfolio, which is crucial for its competitive positioning in the market [11].
Enzo Biochem(ENZ) - 2024 Q3 - Quarterly Report
2024-06-13 20:15
Revenue Performance - Product revenues increased to $8.0 million in the 2024 period, up 7% from $7.5 million in the 2023 period, with a 40% revenue increase in European markets[133] - Product revenues increased to $24.4 million in the 2024 period, up 10% from $22.1 million in the 2023 period, driven by a 10% increase in the US market and a 16% increase in the European market[146] Profitability - The gross profit margin for Products improved to approximately 47% in the 2024 period from 40% in the 2023 period, driven by a favorable product mix and lower input costs[134] - The cost of product revenues decreased to $13.0 million in the 2024 period, a reduction of 5% from $13.7 million in the 2023 period, resulting in a gross profit margin improvement to approximately 47%[147] Expenses - Research and development expenses decreased by 32% to $0.6 million in the 2024 period from $0.9 million in the 2023 period, with no activities related to translational research due to exiting the clinical reference business[135] - Research and development expenses were reduced to $2.0 million in the 2024 period, down 25% from $2.7 million in the 2023 period, following the cessation of translation product development[148] - Selling, general and administrative expenses fell by 28% to $4.5 million in the 2024 period from $6.2 million in the 2023 period, primarily due to reduced consulting fees and lower salaries[136] - Selling, general and administrative expenses decreased to $16.6 million in the 2024 period, a decline of 3% from $17.1 million in the 2023 period, primarily due to lower consulting fees and reduced salaries[149] - Legal and related expenses decreased by 84% to $0.7 million in the 2024 period from $4.3 million in the 2023 period, reflecting reduced legal needs following the Asset Purchase Agreement[137] - Legal and related expenses significantly decreased to $2.5 million in the 2024 period, down 59% from $6.2 million in the 2023 period, reflecting reduced legal needs[150] Interest and Financial Adjustments - Interest income increased to $0.7 million in the 2024 period compared to a net interest expense of $0.1 million in the 2023 period, a favorable variance of $0.8 million[138] - Interest income increased to $2.6 million in the 2024 period, a favorable variance of $2.5 million compared to $0.1 million in the 2023 period, due to net proceeds from the Asset Purchase Agreement[151] - The company recorded a fair value adjustment charge of approximately $0.4 million for the Debentures as of April 30, 2024[139] Foreign Exchange Impact - The foreign exchange loss for the Products segment was $0.5 million in the 2024 period, compared to a gain of $0.4 million in the 2023 period, resulting in an unfavorable variance of $0.9 million[140] - The foreign exchange loss for the 2024 period was approximately $0.9 million, compared to a gain of $1.0 million in the 2023 period, resulting in an unfavorable variance of $1.9 million[153] Cash Flow and Financial Position - As of April 30, 2024, the company's cash and cash equivalents totaled $57.2 million, down from $83.4 million as of July 31, 2023, primarily due to net losses and cash used to pay down liabilities[154] - Net cash used in operating activities was $25.2 million in the 2024 period, an increase of $5.3 million compared to $19.9 million in the 2023 period, attributed to the paydown of accounts payable[155] Legal Matters - A ransomware attack in April 2023 affected approximately 2,470,000 individuals' clinical test information, with potential costs covered up to $3 million by the company's cybersecurity insurance[128] - The company is involved in ongoing legal matters, including class action lawsuits related to a ransomware attack, which may impact future financial obligations and profitability[157] Business Transactions - The company completed the sale of its Clinical Services business to Labcorp for an aggregate purchase price of $113.25 million in cash, effective July 24, 2023[125]